Adherence profiles and therapeutic responses of treatment - naive HIV - 1 infected patients starting boosted atazanavir - based therapy : the ANRS 2 134 - COPHAR 3 trial 3 4
نویسندگان
چکیده
4 Jean-Jacques Parienti, Aurélie Barrail-Tran, Xavier Duval, Georges Nembot, Diane 5 Descamps, Marie Vigan, Bernard Vrijens, Xavière Panhard, Anne-Marie Taburet, France 6 Mentré, Cécile Goujard 7 8 a Univ Paris Diderot, Sorbonne Paris Cité, UMR 738, F-75018 Paris, France; INSERM, UMR 9 738, F-75018 Paris 10 b Department of Biostatistics and Clinical Research, Faculté de Médecine de Caen, Centre 11 Hospitalier Universitaire de Caen Côte de Nacre, Caen 12 c Department of Clinical Pharmacy, Bicêtre Hospital, Assistance Publique Hôpitaux de Paris 13 (AP-HP), Le Kremlin-Bicêtre 14 d Department of Clinical Pharmacy, EA 4123, Faculté de Pharmacie, Univ Paris-Sud 11, 15 Chatenay Malabry 16 e Department of Virology, Bichat-Claude Bernard Hospital, AP-HP, Paris 17 f AARDEX Group, Sion, Switzerland 18 g Department of Internal Medicine, Bicêtre Hospital, AP-HP, Le Kremlin-Bicêtre 19 h INSERM U1018, CESP, and Univ Paris-Sud 11, Le Kremlin Bicêtre, France 20 21 Running Title : Adherence profile to atazanavir 22 23 Corresponding footnote: Dr. Jean-Jacques Parienti, INSERM U738, Université Paris Diderot, 24 Sorbonne Paris Cité, Site Bichat, 16, Avenue Henri Huchard, Paris, France 25 E-mail: [email protected] 26 27 Financial Support and Conflicts of Interest: This investigation was supported in part by a 28 research grant from the Agence Nationale de Recherche contre le Sida. JJP is supported by 29 ATIP Avenir: "Modélisation, Aide à la Décision, et Coût-Efficacité en Maladies 30 Infectieuses", INSERM U738. All authors have no conflict of interest to declare. 31 32 Copyright © 2013, American Society for Microbiology. All Rights Reserved. Antimicrob. Agents Chemother. doi:10.1128/AAC.02605-12 AAC Accepts, published online ahead of print on 4 March 2013
منابع مشابه
Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.
Antiretroviral drug combinations that include two nucleoside reverse transcriptase inhibitors and a protease inhibitor (PI) can suppress HIV replication to undetectable levels, improving the prognosis of HIV-infected individuals. The aim of therapy is complete virological suppression, with a current goal of <50 copies/mL HIV-1 RNA, in order to minimize the occurrence of drug resistance. Improve...
متن کاملEfficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
OBJECTIVES We evaluate the efficacy and tolerability of ritonavir-boosted dual protease inhibitor as a nucleoside reverse transcriptase inhibitor-sparing regimen in a prospective open-label randomized pilot trial in antiretroviral-naive patients. METHODS Thirty patients received fosamprenavir/atazanavir/ritonavir (Group 1) and 31 patients received saquinavir/atazanavir/ritonavir (Group 2). Th...
متن کاملVirologic and immunologic responses in treatment-naive patients to ritonavir-boosted atazanavir or efavirenz with a common backbone.
BACKGROUND Atazanavir boosted with ritonavir (ATV/r) and efavirenz (EFV) are both recommended as first-line therapies for HIV-infected patients. We compared the 2 therapies for virologic efficacy and immune recovery. METHODS We included all treatment-naïve patients in the Swiss HIV Cohort Study starting therapy after May 2003 with either ATV/r or EFV and a backbone of tenofovir and either emt...
متن کاملSerum lipid profiles among patients initiating ritonavir-boosted atazanavir versus efavirenz-based regimens
BACKGROUND Antiretrovirals used to treat HIV-infected patients have the potential to adversely affect serum lipid profiles and increase the risk of cardiovascular disease which is an emerging concern among HIV-infected patients. Since boosted atazanavir and efavirenz are both considered preferred antiretrovirals a head to head comparison of their effects on serum lipids is needed. AIM The pri...
متن کاملPossible Atazanavir-Induced Cholelithiasis in a Pregnant Woman: A Case Report.
For treatment-naive adult patients infected with HIV, the first-line antiretroviral regimen consists of 2 nucleoside reverse transcriptase inhibitors in combination with an integrase inhibitor or a boosted darunavir regimen.1 As of April 2015, the US Department of Health and Human Services replaced atazanavir with an alternative protease inhibitor regimen in its guidelines for adults and adoles...
متن کامل